A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Clinical trial NCT05296798 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05296798
- Sponsor
- Hoffmann-La Roche
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-18
- Primary completion
- 2027-10-31
- Enrollment
- 922
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.